Welcome to Aclipse Therapeutics

Aclipse Therapeutics develops novel and highly differentiated therapeutics to treat diseases with significant unmet medical needs. Our vision is to combine new understanding of disease-relevant biological pathways and development of innovative drug candidates coupled with precision medicine approaches, to reduce development risk and increase probability of clinical success.

Science and Innovation

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and death of nerve cells. There is an urgent need for effective neuroprotective therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).

Data from disease model systems and from human biosamples provide strong evidence for a role of redox imbalance, inflammation, mitochondrial dysfunction and altered proteostasis including autophagy and mitophagy, as four key main drivers in the pathobiology of neurodegenerative diseases. Compounds which activate the nuclear factor erythroid 2-related factor 2 (NRF2) and heat shock factor 1 (HSF1) pathways have beneficial effects on all four of these key main drivers of neurodegeneration.


Aclipse’s lead drug product is M102, a disease-modifying therapeutic candidate for the treatment of ALS, also known as motor neuron disease (MND) or Lou Gehrig’s disease.


Aclipse management team has extensive experience in pharmaceutical research, regulatory and clinical development, manufacturing, and drug product introductions. In addition, our team has a strong proven track record in business development, including in- and out-licensing, acquisitions, and collaborations. Aclipse management team recently exited Thar Pharmaceuticals (acquired by Grünenthal GmbH) and Lev Pharmaceuticals (now Takeda). The Aclipse team has collectively managed 12 orphan drug development programs.
We're here to answer any questions.
Looking to connect with us?